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Abstract—Recent studies in breast cancer domains have iden-
tified seven distinct clinical phenotypes (groups) using immuno-
histochemical analysis and a variety of unsupervised learning
techniques. Consensus among the clustering algorithms has been
used to categorise patients into these specific groups, but often at
the expenses of not classifying all patients. It is known that fuzzy
methodologies can provide linguistic based classification rules to
ease those from consensus clustering. The objective of this study
is to present the validation of a recently developed extension
of a fuzzy quantification subsethood-based algorithm on three
sets of newly available breast cancer data. Results show that
our algorithm is able to reproduce the seven biological classes
previously identified, preserving their characterisation in terms
of marker distributions and therefore their clinical meaning.
Moreover, because our algorithm constitutes the fundamental
basis of the newly developed Nottingham Prognostic Index Plus
(NPI+), our findings demonstrate that this new medical decision
making tool can help moving towards a more tailored care in
breast cancer.
Index Terms—Rule-based classification, Fuzzy rules, Valida-
tion, Breast cancer
I. INTRODUCTION
Breast cancer is the most common cancer and cause of
cancer death in women in the UK [1]. It is regarded as a
heterogeneous group of diseases with complex and distinctive
underlying molecular pathogenesis [2]. Computational meth-
ods have been developed to address this heterogeneity, to
assist in predicting outcome, and to support clinical decision
making in breast cancer management. In particular, clustering
approaches have become more and more popular, and have
been used on gene expression profiling and on patient tumour
samples. We and others have applied protein biomarker panels,
with known relevance to breast cancer, to large numbers of
cases using tissue microarrays, exploring the existence and
clinical significance of distinct breast cancer classes through
clustering approaches [3] and consensus clustering method-
ologies [4]. This led to the identification of novel cancer
subtypes [5], although a large proportion (38%) of patients
presented mixed characteristics and remained unclassified.
Subsequent studies [6], [7] have refined previous breast cancer
classifications introducing a seventh biological group and re-
ducing the number of patients ‘not classified’ in any particular
class.
Alternative approaches may be used to ‘soften’ the rules of
consensus clustering, like fuzzy rule-based systems (FRBS),
which are the focus of our study. FRBS have been recently
applied to classification problems in which non-fuzzy input
instances need to be assigned to one of a given set of classes
to produce high classification accuracy. Many approaches have
been proposed for generating and learning fuzzy if-then rules
from numerical data for classification problems [8].
The purpose of this paper is to present the validation of a
previously developed data-driven subsethood-based fuzzy rule
induction algorithm, named ‘fuzzy quantification subsethood-
based algorithm’ (fuzzyQSBA) [7], [9] over three new in-
dependent sets of breast cancer data. The main intention of
the proposed technique was to build a model that could be
easily interpreted by non-experts in classification systems to
refine previously identified breast cancer treatment groups [6].
Those seven breast cancer classes were derived using clinical
expert knowledge, considering patient outcomes and response
to treatments.
The structure of the paper is as follows: in section II,
the methodology used and the data available are presented;
the fuzzyQSBA algorithm is also quickly recalled and de-
scribed. Results of the application of the algorithm to the new
breast cancer data sets are reported in section III. Section IV
concludes the paper with a discussion of the results, and
suggestions for future work.
II. MATERIALS AND METHODS
The dataset used for the development of the algorithm
presented in [7] consisted of a cohort of 1,073 patients
presented at Nottingham City Hospital between 1986 and 1998
with primary operable breast cancer. Among all the available
information, the following ten markers were considered:
1) Estrogen Receptor (ER)
2) Progesterone Receptor (PgR)
3) cytokeratin 7/8 (CK7/8)
4) cytokeratin 5/6 (CK5/6)
5) EGFR
6) c-erbB2 (HER2)
7) c-erbB3 (HER3)
8) c-erbB4 (HER4)
9) p53
10) Mucin1 (MUC1)
This panel of protein biomarkers has been recently used to
identify core classes which are clinically meaningful and well-
characterised [6].
An additional set of 238 patients from the same Notting-
ham series for which immunohistochemistry data for the ten
biomarkers was available is considered in this study as a first
validation cohort for the fuzzyQSBA algorithm. The second
independent external validation data set has been provided
from Edinburgh, which comprised a cohort of 885 patients
treated by breast conservation surgery, axillary node sampling
or clearance, and whole breast radiotherapy between 1981–
98 in Edinburgh (Edinburgh Breast Conservation Series) [10].
TMAs of the Edinburgh series were also stained for the same
aforementioned biomarkers in Nottingham using the same pro-
cedures as previously described in [6], [11]. The third series of
breast cancer biomarkers was collected in Hungary. This series
comprised 368 screen detected and symptomatic consecutive
cases diagnosed with primary breast cancer between 1999–
2002 and operated at the Buda MA´V Hospital, Budapest,
Hungary. A total of 271 cases were assembled in TMAs, the
remaining cases were not included due to technical reasons or
lack of relevant data [12].
Some missing values were present in the data sets con-
sidered, but only for specific markers. Records for ER, PgR,
and HER2 were available for all patients in the three cohorts
considered, making it possible to proceed with the validation
of the fuzzyQSBA algorithm. The process in which miss-
ing values were dealt with is explained below when the
fuzzyQSBA algorithm is recalled.
The same seven classes previously identified in [6] were
considered, to be classified using the specified ten markers.
The original distribution of patients in these seven groups is
presented in Table I. It can be seen that 38 patients remained
unclassified (either distant from all classes or presenting mixed
characteristics).
TABLE I
ORIGINAL DATA CLASS DISTRIBUTIONS
(‘NC’ MEANS NOT CLASSIFIED).
Class Patients
1 (Luminal A) 288 (26.8%)
2 (Luminal N) 205 (19.1%)
3 (Luminal B) 186 (17.3%)
4 (Basal p53 altered) 113 (10.5%)
5 (Basal p53 normal) 96 (9.0%)
6 (HER2+/ER+) 62 (5.8%)
7 (HER2+/ER-) 85 (7.9%)
NC 38 (3.5%)
Total 1073
The fuzzyQSBA algorithm uses fuzzy subsethood measures,
rule induction approaches, and fuzzy quantifiers to produce a
list of linguistic rules which can then be used for classification
purposes. The algorithm and its background theory are fully
described in [7], together with a class assignment procedure
used to obtain a ‘hard’ classification into groups. A schematic
representation of the whole process is reported in Fig. 1.
The overall methodology requires different steps: firstly,
fuzzy sets ‘high’ and ‘low’ are defined for each variable
(biomarker) and the corresponding membership functions are
computed. H-scores values for each biomarker in the training
and testing data are therefore changed to two different values
corresponding to the degree of membership to each set ‘high’
and ‘low’. As mentioned before, during the validation phase,
some missing records were present in the data sets used for
testing. To deal with missing information, and to tackle uncer-
tainty, the following procedure was used: a membership value
equal to 1 was assigned to the missing entries for both the
functions ‘high’ and ‘low’ rather than using sigmoid equations.
By following the overall procedure so far, ‘modified’ training
and testing data sets are produced.
Then, using some pre-specified t–norm and t–conorm, the
fuzzy subsethood values (needed to generate the fuzzy rules)
are computed from the ‘modified’ training data, and the
fuzzy rules are also obtained. The number of rules created
corresponds to the number of possible classification outcomes.
In our case, seven breast cancer classes needed to be sought,
so seven rules were created. To generate the fuzzy rules,
quantifiers need to be placed before instances of a fuzzy set.
An example of a quantified statement is “most students who
get a high score are young”, where ‘most’ is the quantifier,
while ‘high’ and ‘young’ are the fuzzy sets.
The last step of the algorithm concerns the application of
the fuzzy rules to the ‘modified’ testing data to generate the
membership values of every data point (patient) to each of the
seven classes. A list of possibility values is then ‘appended’ to
each patient to represent their degree of membership to each
biological group. Possibilities are real numbers between 0 and
1, indicating the degree of membership of a specific data point
to a particular class. To derive a ‘hard’ classification where
each patient is assigned to only a particular group, the ‘class
assignment algorithm’ as described in [7] is employed.
For the purpose of this paper the algorithm has been trained
on the original Nottingham data [6], [7] and tested inde-
pendently on the new Nottingham, Edinburgh and Hungary
validation series. The whole algorithm and the validation
process were coded using R, a free software environment for
computing and graphics [13].
III. RESULTS
The fuzzyQSBA algorithm was applied to the new Notting-
ham validation cohort first, then to the Edinburgh series, and
finally to the cohort from Hungary. The classification outcomes
are reported in Table II, Table III and Table IV respectively.
It can be seen that, although the percentage of patients in
each class is not always consistent with the original data, the
Fig. 1. Framework of fuzzyQSBA.
TABLE II
NEW NOTTINGHAM DATA CLASS DISTRIBUTIONS
(‘NC’ MEANS NOT CLASSIFIED).
Class Patients
1 (Luminal A) 68 (28.6%)
2 (Luminal N) 58 (24.4%)
3 (Luminal B) 39 (16.4%)
4 (Basal p53 altered) 17 (7.1%)
5 (Basal p53 normal) 28 (11.8%)
6 (HER2+/ER+) 8 (3.3%)
7 (HER2+/ER-) 8 (3.4%)
NC 12 (5.0%)
Total 238
TABLE III
EDINBURGH DATA CLASS DISTRIBUTIONS
(‘NC’ MEANS NOT CLASSIFIED).
Class Patients
1 (Luminal A) 241 (27.2%)
2 (Luminal N) 168 (19.0%)
3 (Luminal B) 157 (17.7%)
4 (Basal p53 altered) 102 (11.5%)
5 (Basal p53 normal) 79 (8.9%)
6 (HER2+/ER+) 32 (3.6%)
7 (HER2+/ER-) 55 (6.2%)
NC 51 (5.8%)
Total 885
seven classes in all three validation cohorts clearly retain their
characterisation, as shown in Fig. 2, in Fig. 3, and in Fig. 4
compared with the original Nottingham data shown in Fig. 5.
Classes 1, 2 and 3 have a luminal profile, because they are
characterised by high luminal CK7/8 and hormone receptor
(ER and PgR) expression. Classes 1 and 3 (Luminal A and
luminal B tumours) show high expression of CK7/8, ER,
TABLE IV
HUNGARY DATA CLASS DISTRIBUTIONS
(‘NC’ MEANS NOT CLASSIFIED).
Class Patients
1 (Luminal A) 84 (31.0%)
2 (Luminal N) 32 (11.8%)
3 (Luminal B) 65 (24.0%)
4 (Basal p53 altered) 18 (6.6%)
5 (Basal p53 normal) 36 (13.3%)
6 (HER2+/ER+) 15 (5.5%)
7 (HER2+/ER-) 16 (5.9%)
NC 5 (1.9%)
Total 271
HER3 and HER4 but are separated by relatively lower levels
of PgR expression in luminal B compared with luminal A
tumours. In contrast, class 2 (luminal N tumours) shows differ-
ential expression of HER3 and HER4. Classes 4 and 5 (basal
groups of tumour) are characterised by low luminal cytokeratin
and high basal expression (CK5/6) along with showing a
triple-negative phenotype (i.e., ER, PgR and HER2 are all
under-expressed). They are, however, separated by p53 protein
expression levels, resulting in the expression of either high
p53 (basal-p53 altered) or low p53 (basal-p53 normal). The
remaining classes (6 and 7) are characterised by high luminal
cytokeratin and HER2 over-expression, resulting in a HER2+
profile. They are however distinguished in the expression of
hormone receptors, with class 6 expressing ER (HER2+/ER+),
and class 7 showing an ER- phenotype (HER2+/ER-). The
unassigned patients show heterogenic expression of all ten
markers.
IV. DISCUSSION
In this paper we presented the validation of a data-
driven subsethood-based fuzzy rule induction algorithm,
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Fig. 2. Boxplots of ten markers (whole data and grouped by class) for the new Nottingham data (238 patients).
fuzzyQSBA [7], to new independent breast cancer data sets.
Results show that the method is able to classify patients
into the seven treatment groups previously identified [6] and
demonstrate that the output classification meets the initial
algorithm requirements for all the new validation series (Not-
tingham, Edinburgh, Hungary).
Several studies have been published in recent years inves-
tigating the usage of protein biomarker panels (with known
relevance to breast cancer), in large numbers of cases using
tissue microarrays, to highlight the existence and significance
(in clinical terms) of distinct breast cancer classes [3], [5],
[6]. However, although several cancer classes were clearly
identified, many patients were left in a mixed-classified or
unclassified group.
To ease the strict rules of hard-clustering, the use of fuzzy
methodologies have become more and more important in
addressing classification problems. In particular, FRBS have
been employed to obtain high classification accuracy through
linguistic rulesets. The fuzzyQSBA algorithm [8] is an exam-
ple of such systems, which uses continuous fuzzy quantifiers
to create the ruleset. This method, together with the class
assignment algorithm presented in [7], has been used to obtain
a refinement of the seven breast cancer classes introduced
in [6]. In addition, the seven subclasses have significant
differences in tumour characteristics and in clinical outcome,
as reported in our most recent studies [14]–[16]. The results
reported in this paper do not show the same percentage of
patients (although somehow similar) in each class as in [7];
this can be due to the small size of the new Nottingham cohort
and to some differences in the overall distribution of size, stage
and grade of tumours for the Edinburgh and Hungary series
which had an impact on the value of the biological markers.
However, results for all validation cohorts do show how the
distribution of the ten markers in the seven classes follow those
previously presented and how the original requirements of the
fuzzyQSBA algorithm (as reported in [7]) have been met for
each validation cohort. An interpretation of the seven classes
derived for the Edinburgh and Hungary series from a clinical
perspective is out of the scope of this paper, but is presented
in [15] and in [16] respectively.
In conclusion, we demonstrated that our methodology is
capable to maintain the chracteristics of each of the seven
breast cancer classes. Future work will focus on further
validation of the algorithm on more external cohorts of patients
from European and American centres; data for this additional
validation are being currently acquired and gathered. We will
also work on determining whether novel markers, such as
Ki67, need to be incorporated in the model itself, as additional
variables or to substitute some of the existing ones.
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Fig. 3. Boxplots of ten markers (whole data and grouped by class) for the Edinburgh data (885 patients).
Hungary for collecting and providing the data and for helping
with the clinical interpretation of the seven biological classes.
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Fig. 4. Boxplots of ten markers (whole data and grouped by class) for the Hungary data (271 patients).
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Fig. 5. Boxplots of ten markers (whole data and grouped by class) for the original Nottingham data (1073 patients).
